Jia Wu, PhD
Department of Imaging Physics, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Associate Professor, Department of Department Thoracic-Head & Neck Medical Oncology, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 2013 | University of Pittsburgh, Pittsburgh, Pennsylvania, US, Ph.D. in Civil & Bioengineering |
| 2009 | Harbin Institute of Technology, Heilongjiang, CN, M.S. in Mechanical Engineering |
| 2007 | Harbin Institute of Technology, Heilongjiang, CN, BS in Mechanical Engineering |
Experience & Service
Academic Appointments
Assistant Professor, Department of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2024
Assistant Professor, Department of Thoracic-Head & Neck Med Onc, The University of Texas MD Anderson Cancer Center, Houston, Texas, 2020 - 2024
Instructor, Department of Radiation Oncology, Stanford University, Palo Alto, CA, 2018 - 2020
Institutional Committee Activities
Committee Member, Gulf Coast Consortia Translational Imaging Steering Committee, 2022 - Present
Committee Member, Breast Cancer Moon Shot IAB Committee, 2021 - Present
Honors & Awards
| 2024 | Invited Preview of Research Paper, Cell Reports Medicine |
| 2024 | Editor’s Choice of Research Paper, Annals of Oncology |
| 2024 | Hearst Health Prize Finalist |
| 2023 | Faculty Scholar Award President's Recognition of Faculty Excellence, The University of Texas MD Anderson Cancer Center |
| 2023 | Scholar-In-Training Award (Senior Author), AACR |
| 2023 | Editor's Recognition Awards with Distinction, RSNA Radiology Journal Office |
| 2023 | Invited Commentary of Research Paper, The Lancet Digital Health |
| 2022 | Invited Commentary of Research Paper, The Journal of Pathology |
| 2022 | Monthly Readers’ Choice of Research Paper, Modern Pathology |
| 2022 | DI Outstanding Jr. Faculty Award, The University of Texas MD Anderson Cancer Center |
| 2021 | UT Rising STARs Award, The University of Texas System |
| 2021 | NCI Awardee Skills Consortium (NASDC) |
| 2021 - 2023 | Rexanna's Foundation Award for Fighting Lung Cancer |
| 2021 | Goldwater Scholar (Research Mentor) |
| 2021 | News and Views of Research Paper, Nature Machine Intelligence |
| 2019 | Editor's Recognition Awards with Special Distinction, RSNA Radiology Journal Office |
| 2018 | Research Career Accelerator Program, Stanford Center for Clinical & Translational Research & Education |
| 2018 | Pathway to Independence Award (K99/R00), NIH/NCI |
| 2017 | Introduction to Academic Radiology for Scientists Program (ITARSc), RSNA |
| 2017 | Featured Research Paper, International Society for Magnetic Resonance in Medicine |
| 2017 | Outstanding Reviewer Awards, Physics in Medicine and Biology |
| 2017 | Outstanding Reviewer Awards, Computers in Biology and Medicine |
| 2016 | Editorial Highlighted Paper and News Release, RSNA Radiology Journal Office |
| 2015 | Final List of Best Student Paper Award, SPIE Medical Imaging |
| 2015 | Outstanding Reviewer Awards, Pattern Recognition |
| 2013 | Featured Research Paper, Computer Methods in Biomechanics and Biomedical Engineering, Imaging & Visualization Journal Office |
| 2011 | Travel Award, 11th and 12th US National Congress on Computational Mechanics |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Li, H, Salehjahromi, M, Godoy, M, Qin, K, Plummer, CM, Zhang, Z, Hong, L, Heeke, S, Le, X, Vokes, N, Zhang, B, Araujo, HA, Altan, M, Wu, CC, Antonoff, MB, Ostrin, EJ, Gibbons, DL, Heymach, JV, Lee, JJ, Gerber, DE, Wu, J, Zhang, J. Lung Cancer Risk Prediction in Patients with Persistent Pulmonary Nodules Using the Brock Model and Sybil Model. Cancers 17(9), 2025. e-Pub 2025.
- Heeke, S, Gandhi, S, Tran, HT, Lam, VK, Byers, LA, Gibbons, DL, Gay, CM, Altan, M, Antonoff, MB, Le, X, Tu, J, Saad, M, Pek, M, Poh, J, Ngeow, KC, Tsao, A, Cascone, T, Vailati Negrao, M, Wu, J, Blumenschein, GR, Heymach, JV, Elamin, YY. Longitudinal Tracking of ALK-Rearranged NSCLC From Plasma Using Circulating Tumor RNA and Circulating Tumor DNA. JTO Clinical and Research Reports 6(4), 2025. e-Pub 2025. PMID: 40160974.
- Wang X, Dong J, Li JR, Lin Y, Sahoo B, Li Y, Liu Y, Ripley RT, Wu J, Zhang J, Amos CI, Cheng C. Cytotoxic and regulatory T cell interactions calculated from image mass cytometry predict immunochemotherapy response in triple-negative breast cancer. Cancer Commun (Lond) 45(4):392-396, 2025. e-Pub 2025. PMID: 39749721.
- Hong, L, Patel, S, Drusbosky, L, Xiong, Y, Chen, R, Geng, R, Heeke, S, Nilsson, M, Wu, J, Heymach, JV, Wang, Y, Zhang, J, Le, X. Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39354054.
- Li, C, Nguyen, TT, Li, J, Song, X, Fujimoto, J, Little, L, Gumb, C, Chow, CW, Wistuba, II, Futreal, A, Zhang, J, Hubert, SM, Heymach, JV, Wu, J, Amos, CI, Zhang, J, Cheng, C. Multiregional transcriptomic profiling provides improved prognostic insight in localized non-small cell lung cancer. npj Precision Oncology 8(1), 2024. e-Pub 2024. PMID: 39369068.
- Zhou, N, Leung, CH, William Jr, WN, Weissferdt, A, Pataer, A, Godoy, M, Carter, B, Fossella, FV, Tsao, A, Blumenschein, GR, Le, X, Zhang, J, Skoulidis, F, Kurie, JM, Altan, M, Lu, C, Glisson, BS, Byers, LA, Elamin, YY, Mehran, RJ, Rice, DC, Walsh, GL, Hofstetter, WL, Roth, JA, Tran, HT, Wu, J, Solis Soto, LM, Kadara, HN, Swisher, SG, Vaporciyan, AA, Gibbons, DL, Lin, HY, Jack Lee, J, Heymach, JV, Vailati Negrao, M, Sepesi, B, Cascone, T. Impact of select actionable genomic alterations on efficacy of neoadjuvant immunotherapy in resectable non-small cell lung cancer. Journal for immunotherapy of cancer 12(10), 2024. e-Pub 2024. PMID: 39448200.
- Alahdab, F, Saad, M, Ahmed, AI, Al Tashi, Q, Aminu, M, Han, Y, Moody, JB, Murthy, VL, Wu, J, Al-Mallah, MH. Development and validation of a machine learning model to predict myocardial blood flow and clinical outcomes from patients’ electrocardiograms. Cell Reports Medicine 5(10), 2024. e-Pub 2024. PMID: 39326409.
- Waqas, M, Ahmed, SU, Tahir, MA, Wu, J, Qureshi, R. Exploring Multiple Instance Learning (MIL). Expert Systems with Applications 250, 2024. e-Pub 2024.
- Sun, P, Gu, KJ, Zheng, G, Sikora, AG, Li, C, Zafereo, M, Wei, P, Wu, J, Shete, S, Liu, J, Li, G. Genetic variations associated with telomere length predict the risk of recurrence of non-oropharyngeal head and neck squamous cell carcinoma. Molecular Carcinogenesis 63(9):1722-1737, 2024. e-Pub 2024. PMID: 38837510.
- Soto-Lanza F, Glick L, Chan C, Zhong L, Wilson N, Faiz S, Gandhi S, Naing A, Heymach JV, Shannon VR, Franco-Vega M, Liao Z, Lin SH, Palaskas NL, Wu J, Shroff GS, Altan M, Sheshadri A. Long-Term Clinical, Radiological, and Mortality Outcomes Following Pneumonitis in Nonsmall Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors: A Retrospective Analysis. Clin Lung Cancer 25(7):624-633.e2, 2024. e-Pub 2024. PMID: 39183094.
- Zhang, B, Li, C, Wu, J, Zhang, J, Cheng, C. DeepCG. International journal of cancer 154(12):2151-2161, 2024. e-Pub 2024. PMID: 38429627.
- Seth, S, Chen, R, Liu, Y, Fujimoto, J, Hong, L, Reuben, A, Varghese, S, Behrens, MC, McDowell, TL, Solis Soto, LM, Haymaker, CL, Weissferdt, A, Kalhor, N, Wu, J, Le, X, Vokes, N, Cheng, C, Heymach, JV, Gibbons, DL, Futreal, A, Wistuba, II, Kadara, HN, Zhang, J, Moran, C, Zhang, J. Integrative genomic and transcriptomic profiling of pulmonary sarcomatoid carcinoma identifies molecular subtypes associated with distinct immune features and clinical outcomes. Cancer Innovation 3(3), 2024. e-Pub 2024. PMID: 38947760.
- Niu, Z, Sun, P, Zafereo, M, Liu, H, Wei, P, Wu, J, Gross, N, Shete, S, Wei, Q, Zheng, G, Sikora, AG, Calin, GA, Li, G. TGF-β1 and TGF-βR1 variants are associated with clinical outcomes in smoking-related head and neck cancer patients treated with chemoradiation through modulating microRNA-mediated regulation. Cancer Immunology, Immunotherapy 73(5), 2024. e-Pub 2024. PMID: 38554185.
- Waqas, M, Tahir, MA, Author, MD, Al-Maadeed, S, Bouridane, A, Wu, J. Simultaneous instance pooling and bag representation selection approach for multiple-instance learning (MIL) using vision transformer. Neural Computing and Applications 36(12):6659-6680, 2024. e-Pub 2024.
- Salehjahromi, M, Karpinets, T, Sujit, S, Qayati, M, Chen, P, Aminu, M, Saad, MB, Bandyopadhyay, R, Hong, L, Sheshadri, A, Lin, J, Antonoff, MB, Sepesi, B, Ostrin, EJ, Toumazis, I, Huang, P, Cheng, C, Cascone, T, Vokes, N, Behrens, C, Siewerdsen, JH, Hazle, JD, Chang, JY, Zhang, J, Lu, Y, Godoy, M, Chung, C, Jaffray, D, Wistuba, II, Lee, JJ, Vaporciyan, AA, Gibbons, DL, Gladish, G, Heymach, JV, Wu, CC, Zhang, J, Wu, J. Synthetic PET from CT improves diagnosis and prognosis for lung cancer. Cell Reports Medicine 5(3), 2024. e-Pub 2024. PMID: 38471502.
- Zafar, A, Aftab, D, Qureshi, R, Fan, X, Chen, P, Wu, J, Ali, H, Nawaz, S, Khan, S, Shah, M. Single Stage Adaptive Multi-Attention Network for Image Restoration. IEEE Transactions on Image Processing 33:2924-2935, 2024. e-Pub 2024. PMID: 38598372.
- Li, H, Hu, X, Ning, M, Fuller, GN, Stewart, J, Gilliam, JC, Wu, J, Le, X, Vaporciyan, AA, Lee, JJ, Gibbons, DL, Heymach, JV, Futreal, A, Zhang, J. Case report. Frontiers in Oncology 14, 2024. e-Pub 2024. PMID: 38590653.
- Vokes NI, Galan Cobo A, Fernandez-Chas M, Molkentine D, Trevino S 3rd, Druker V, Qian Y, Patel S, Schmidt S, Hong L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, Lee JJ, Negrao MV, Gibbons DL, Vaporciyan A, Le X, Wu J, Zhang J, Rigney U, Iyer S, Dean E, Heymach JV. ATM Mutations Associate with Distinct Co-Mutational Patterns and Therapeutic Vulnerabilities in NSCLC. Clin Cancer Res 29(23):4958-4972, 2023. e-Pub 2023. PMID: 37733794.
- Chen, P, Rojas Alvarez, F, Hu, X, Serrano, A, Zhu, B, Chen, H, Hong, L, Bandyoyadhyay, R, Aminu, M, Kalhor, N, Lee, JJ, El Hussein, S, Khoury, J, Pass, HI, Moreira, AL, Velcheti, V, Sterman, DH, Fukuoka, J, Tabata, K, Su, D, Ying, L, Gibbons, DL, Heymach, JV, Wistuba, II, Fujimoto, J, Solis Soto, LM, Zhang, J, Wu, J. Pathomic Features Reveal Immune and Molecular Evolution From Lung Preneoplasia to Invasive Adenocarcinoma. Modern Pathology 36(12), 2023. e-Pub 2023. PMID: 37678674.
- Gan, J, Wang, H, Yu, H, He, Z, Zhang, W, Ma, K, Zhu, L, Bai, Y, Zhou, Z, Yullie, A, Bai, X, Wang, MW, Yang, D, Chen, Y, Chen, G, Lasenby, J, Cheng, C, Wu, J, Zhang, J, Wang, X, Chen, Y, Wang, G, Xia, T. Focalizing regions of biomarker relevance facilitates biomarker prediction on histopathological images. iScience 26(10), 2023. e-Pub 2023. PMID: 37767002.
- Diao S, Chen P, Showkatian E, Bandyopadhyay R, Rojas FR, Zhu B, Hong L, Aminu M, Saad MB, Salehjahromi M, Muneer A, Sujit SJ, Behrens C, Gibbons DL, Heymach JV, Kalhor N, Wistuba II, Solis Soto LM, Zhang J, Qin W, Wu J. Automated Cellular-Level Dual Global Fusion of Whole-Slide Imaging for Lung Adenocarcinoma Prognosis. Cancers (Basel) 15(19), 2023. e-Pub 2023. PMID: 37835518.
- Niu Z, Sun P, Liu H, Wei P, Wu J, Huang Z, Gross N, Shete S, Wei Q, Zafereo M, Calin G, Li AG. Functional genetic variants in TGF-β1 and TGF-βR1 in microRNA binding sites predict outcomes in patients with HPV-positive oropharyngeal squamous cell carcinoma. Clinical Cancer Research 29(16):3081-30091, 2023. e-Pub 2023. PMID: 37327315.
- Sun P, Wei P, Liu H, Wu J, Gross ND, Sikora AG, Wei Q, Shete S, Zafereo ME, Liu J, Li G. GWAS-identified telomere length associated genetic variants predict risk of recurrence of HPV-positive oropharyngeal cancer after definitive radiotherapy. eBioMedicine 94, 2023. e-Pub 2023. PMID: 37487414.
- Qureshi, R, Irfan, M, Gondal, TM, Khan, S, Wu, J, Hadi, MU, Heymach, JV, Le, X, Yan, H, Alam, T. AI in drug discovery and its clinical relevance. Heliyon 9(7), 2023. e-Pub 2023. PMID: 37396052.
- Saad§ MB, Hong§ L, Aminu§ M, Vokes NI, Chen§ P, Salehjahromi§ M, Qin K, Sujit§ SJ, Lu X, Young E, Al-Tashi§ Q, Qureshi§ R, Wu CC, Carter BW, Lin SH, Lee PP, Gandhi S, Chang JY, Li R, Gensheimer MF, Wakelee HA, Neal JW, Lee H, Cheng C, Velcheti V, Lou Y, Petranovic M, Rinsurongkawong W, Le X, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Wistuba II, Hazle JD, Chung C, Jaffray D, Gibbons DL, Vaporciyan A, J Jack Lee J, Heymach JV, Zhang J, Wu J. Predicting benefit from immune checkpoint inhibitors in patients with non-small-cell lung cancer by CT-based ensemble deep learning: a retrospective study. The Lancet Digit. Health 5(7):e404-e420, 2023. e-Pub 2023. PMID: 37268451.
- Al-Tashi§ Q, Saad§ MB, Sheshadri A, Wu CC, Chang JY, Al-Lazikani B, Gibbons C, Vokes NI, Zhang J, J Jack Lee J, Heymach JV, Jaffray D, Mirjalili S, Wu J. SwarmDeepSurv: Swarm Intelligence Advances Deep Survival Network for Prognostic Radiomics Signatures in Four Solid Cancers. Patterns 4(8), 2023. e-Pub 2023. PMID: 37602223.
- Al-Tashi Q, Saad MB, Muneer A, Qureshi R, Mirjalili S, Sheshadri A, Le X, Vokes NI, Zhang J, Wu J. Machine Learning Models for the Identification of Prognostic and Predictive Cancer Biomarkers: A Systematic Review. International Journal of Molecular Sciences 24(9):7781, 2023. e-Pub 2023. PMID: 37175487.
- Cascone T, Leung CH, Weissferdt A, Pataer A, Carter BW, B Godoy MC, Feldman H, William Jr WN, Xi Y, Basu S, Sun JJ, Yadav SS, Rojas Alvarez FR, Lee Y, Mishra AK, Chen L, Pradhan M, Guo H, Sinjab A, Zhou N, Negrao MV, Le X, Gay CM, Tsao AS, Byers LA, Altan M, Glisson BS, Fossella FV, Elamin YY, Jr GB, Zhang J, Skoulidis F, Wu J, Mehran RJ, Rice DC, Walsh GL, Hofstetter WL, Rajaram R, Antonoff MB, Fujimoto J, Solis LM, Parra ER, Haymaker C, Wistuba II, Swisher SG, Vaporciyan AA, Lin HY, Wang J, Gibbons DL, J Jack Lee J, Ajami NJ, Wargo JA, Allison JP, Sharma P, Kadara H, Heymach JV, Sepesi B. Neoadjuvant chemotherapy plus nivolumab with or without ipilimumab in operable non-small cell lung cancer: the phase 2 platform NEOSTAR trial. Nat Med 29(3):593-604, 2023. e-Pub 2023. PMID: 36928818.
- Hong L, Aminu M, Li S, Lu X, Petranovic M, Saad MB, Chen P, Qin K, Varghese S, Rinsurongkawong W, Rinsurongkawong V, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Gandhi SJ, Lin SH, Lee PP, Carter BW, Wu CC, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Gainor JF, Heymach JV, Lou Y, Wu J, Zhang J, Vokes NI. Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. Nat Commun 14(1):695, 2023. e-Pub 2023. PMID: 36755027.
- Al Tashi, Q, Shami, TM, Abdulkadir, SJ, Akhir, EP, Alwadain, A, Alhussain, H, Alqushaibi, A, Rais, HM, Muneer, A, Saad, MB, Wu, J, Mirjalili, S. Enhanced Multi-Objective Grey Wolf Optimizer with Lévy Flight and Mutation Operators for Feature Selection. Computer Systems Science and Engineering 47(2):1937-1966, 2023. e-Pub 2023.
- Qureshi R, Zou B, Alam T, Wu J, Lee V, Yan H. Computational Methods for the Analysis and Prediction of EGFR-mutated Lung Cancer Drug Resistance: Recent Advances in Drug Design, Challenges and Future Prospects. IEEE/ACM Trans Comput Biol Bioinform PP(1):238-255, 2023. e-Pub 2022. PMID: 35007197.
- Qureshi, R, Irfan, M, Ali, H, Khan, A, Nittala, AS, Ali, S, Shah, A, Gondal, TM, Sadak, F, Shah, Z, Hadi, MU, Khan, S, Al Tashi, Q, Wu, J, Bermak, A, Alam, T. Artificial Intelligence and Biosensors in Healthcare and Its Clinical Relevance. IEEE Access 11:61600-61620, 2023. e-Pub 2023.
- Al-Tashi§ Q, Shami TM, Abdulkadir SJ, Patah Akhir EA, Alwadain A, Alhussain H, Alqushaibi A, Rais HM, Muneer§ A, Saad§ MB, Wu J, Mirjalili S. Enhanced Multi‑Objective Grey Wolf Optimizer with Lévy Flight and Mutation Operators for Feature Selection. Computer Systems Science and Engineering, 2023. e-Pub 2023.
- Jiefeng, Hanchen W, Hui Y, Zitong H, Wenjuan Z, Ke M, Lianghui Z, Yutong B, Zongwei Z, Yuille Alan L, Xiang B, Mingwei W, Dehua Y, Yanyan C, Guoan C, Joan L, Chao C, Jia W, Jianjun Z, Xinggang W, Yaobing C, Guoping W, Tian X. Focalizing Regions of Biomarker-Relevance Facilitates Biomarker Prediction on Histopathological Images. iScience, 2023. e-Pub 2023.
- Altan M, Soto F, Xu T, Wilson N, Franco-Vega M, Simbaqueba Clavijo CA, Shannon VR, Faiz SA, Gandhi S, Lin SH, Lopez P, Zhong L, Akhmedzanov F, Godoy MC, Shroff G, Wu J, Khawaja F, Kim ST, Naing A, Heymach JV, Daniel-Macdougall C, Liao Z, Sheshadri A. Pneumonitis after concurrent chemoradiation and immune checkpoint inhibition in locally advanced non-small cell lung cancer. Clinical Oncology, 2023. e-Pub 2023. PMID: 37507279.
- Zheng G, Zhang H, Lin F, Zafereo M, Gross N, Sun P, Liu Y, Sun H, Wu G, Wei S, Wu J, Mao N, Li G, Wu G, Zheng H, Song X. Performance of CT-based deep learning in diagnostic assessment of suspicious lateral lymph nodes in papillary thyroid cancer: a prospective diagnostic study. International Journal of Surgery 109(11):3337-3345, 2023. e-Pub 2023. PMID: 37578434.
- Aminu M, Daver N, Godoy MCB, Shroff G, Wu C, Torre-Sada LF, Goizueta A, Shannon VR, Faiz SA, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim ST, Kontoyiannis DP, Khawaja F, Chung C, Wu J, Sheshadri A. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Front Immunol 14:1249511, 2023. e-Pub 2023. PMID: 37841255.
- Qureshi R, Irfan M, Gondal TM, Khan S, Wu J, Hadi MU, Heymach J, Le X, Yan H, Alam T. AI in Drug Discovery and its Clinical Relevance. Heliyon, 2023. e-Pub 2023.
- Noh S, Bertini C, Mira-Avendano I, Kaous M, Patel B, Faiz SA, Shannon VR, Balachandran DD, Bashoura L, Adachi R, Evans SE, Dickey B, Wu C, Shroff G, Manzano J, Granwehr B, Holloway S, Dickson K, Mohammed A, Muthu M, Song H, Team D, Chung C, Wu J, Lee L, Jiang Y, Khawaja F, Sheshadri A. Interstitial lung abnormalities after hospitalization for COVID-19 in patients with cancer: a prospective cohort study. Cancer Medicine, 2023. e-Pub 2023. PMID: 37592894.
- Qureshi R, Irfan M, Ali H, Khan A, Nittala AS, Ali S, Shah A, Gondal TM, Sadak F, Shah Z, Hadi MU, Khan S, Al-Tashi Q, Wu J, Bermak A, Alam T. Artificial Intelligence and Biosensors in Healthcare and its Clinical Relevance: A Review. IEEE Access, 2023. e-Pub 2023.
- Aminu M, Yadav D, Hong L, Young E, Edelkamp P, Saad M, Salehjahromi M, Chen P, Sujit SJ, Chen MM, Sabloff B, Gladish G, de Groot PM, Godoy MCB, Cascone T, Vokes NI, Zhang J, Brock KK, Daver N, Woodman SE, Tawbi HA, Sheshadri A, Lee JJ, Jaffray D, D Code Team D, Wu CC, Chung C, Wu J. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Cancers (Basel) 15(1), 2022. e-Pub 2022. PMID: 36612278.
- Wu J, Mayer AT, Li R. Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy. Semin Cancer Biol 84:310-328, 2022. e-Pub 2022. PMID: 33290844.
- El Hussein S, Chen P, Medeiros LJ, Hazle JD, Wu J, Khoury JD. Artificial intelligence-assisted mapping of proliferation centers allows the distinction of accelerated phase from large cell transformation in chronic lymphocytic leukemia. Mod Pathol 35(8):1121-1125, 2022. e-Pub 2022. PMID: 35132162.
- Hong L, Lewis WE, Nilsson M, Patel S, Varghese S, Rivera MJ, Du RR, Chen P, Kemp HN, Rinsurongkawong W, Heeke S, Spelman AR, Elamin YY, Negrao MV, Sepesi B, Gibbons DL, Lee JJ, Wu J, Vokes NI, Heymach JV, Zhang J, Le X. Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma. Cancers (Basel) 14(14), 2022. e-Pub 2022. PMID: 35884533.
- Chen P, El Hussein S, Xing F, Aminu M, Kannapiran A, Hazle JD, Medeiros LJ, Wistuba II, Jaffray D, Khoury JD, Wu J. Chronic Lymphocytic Leukemia Progression Diagnosis with Intrinsic Cellular Patterns via Unsupervised Clustering. Cancers (Basel) 14(10), 2022. e-Pub 2022. PMID: 35626003.
- Jimenez JE, Dai D, Xu G, Zhao R, Li T, Pan T, Wang L, Lin Y, Wang Z, Jaffray D, Hazle JD, Macapinlac HA, Wu J, Lu Y. Lesion-Based Radiomics Signature in Pretherapy 18F-FDG PET Predicts Treatment Response to Ibrutinib in Lymphoma. Clin Nucl Med 47(3):209-218, 2022. e-Pub 2022. PMID: 35020640.
- Nguyen TT, Lee HS, Burt BM, Wu J, Zhang J, Amos CI, Cheng C. A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma. Genome Med 14(1):5, 2022. e-Pub 2022. PMID: 35016696.
- El Hussein S, Chen P, Medeiros LJ, Wistuba II, Jaffray D, Wu J, Khoury JD. Artificial intelligence strategy integrating morphologic and architectural biomarkers provides robust diagnostic accuracy for disease progression in chronic lymphocytic leukemia. J Pathol 256(1):4-14, 2022. e-Pub 2022. PMID: 34505705.
- Chen P, Zhang J, Wu J. Artificial Intelligence in Digital Pathology to Advance Cancer Immunotherapy. 21 Century Pathol 2(3), 2022. e-Pub 2022. PMID: 36282981.
- Chen MM, Terzic A, Becker AS, Johnson JM, Wu CC, Wintermark M, Wald C, Wu J. Artificial intelligence in oncologic imaging. Eur J Radiol Open 9:100441, 2022. e-Pub 2022. PMID: 36193451.
- Bai, X, Wang, H, Ma, L, Xu, Y, Gan, J, Fan, Z, Yang, F, Ma, K, Yang, J, Bai, S, Shu, C, Zou, X, Huang, R, Zhang, C, Liu, X, Tu, D, Xu, C, Zhang, W, Wang, X, Chen, A, Zeng, Y, Yang, D, Wang, MW, Holalkere, NS, Halin, NJ, Kamel, IR, Wu, J, Peng, X, Wang, X, Shao, J, Mongkolwat, P, Zhang, J, Liu, W, Roberts, M, Teng, Z, Beer, L, Sanchez, LE, Sala, E, Rubin, D, Weller, A, Lasenby, J, Zheng, C, Wang, J, Li, Z, Schönlieb, CB, Xia, T. Advancing COVID-19 diagnosis with privacy-preserving collaboration in artificial intelligence. Nature Machine Intelligence 3(12):1081-1089, 2021. e-Pub 2021. PMID: 38264185.
- Jiang Y, Jin C, Yu H, Wu J, Chen C, Yuan Q, Huang W, Hu Y, Xu Y, Zhou Z, Fisher GA, Li G, Li R. Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study. Ann Surg 274(6):e1153-61, 2021. e-Pub 2021. PMID: 31913871.
- Tang M, Abbas HA, Negrao MV, Ramineni M, Hu X, Hubert SM, Fujimoto J, Reuben A, Varghese S, Zhang J, Li J, Chow CW, Mao X, Song X, Lee WC, Wu J, Little L, Gumbs C, Behrens C, Moran C, Weissferdt A, Lee JJ, Sepesi B, Swisher S, Cheng C, Kurie J, Gibbons D, Heymach JV, Wistuba II, Futreal PA, Kalhor N, Zhang J. The histologic phenotype of lung cancers is associated with transcriptomic features rather than genomic characteristics. Nat Commun 12(1):7081, 2021. e-Pub 2021. PMID: 34873156.
- Bai X, Wang H, Ma L, Xu Y, Gan J, Fan Z, Yang F, Ma K, Yang J, Bai S, Shu C, Zou X, Huang R, Zhang C, Liu X, Tu D, Xu C, Zhang W, Wang X, Chen A, Zeng Y, Yang D, Wang M, Holalkere N, Halin NJ, Kamel IR, Wu J, Peng X, Wang X, Shao J, Mongkolwat P, Zhang J, Liu W, Roberts M, Teng Z, Beer L, Sanchez LE, Sala E, Rubin DL, Weller A, Lasenby J, Zheng C, Wang J, Li Z, Schönlieb C, Xia T. Advancing COVID-19 diagnosis with privacy-preserving collaboration in artificial intelligence. Nature Machine Intelligence 3(12):1081-9, 2021. e-Pub 2021.
- Chen, P, Aminu, M, El Hussein, S, Khoury, J, Wu, J. CellSpatialGraph. Software Impacts 10, 2021. e-Pub 2021. PMID: 36203948.
- Zhang B, Yao K, Xu M, Wu J, Cheng C. Deep Learning Predicts EBV Status in Gastric Cancer Based on Spatial Patterns of Lymphocyte Infiltration. Cancers (Basel) 13(23):6002, 2021. e-Pub 2021. PMID: 34885112.
- Chen M, Chen R, Jin Y, Li J, Hu X, Zhang J, Fujimoto J, Hubert SM, Gay CM, Zhu B, Tian Y, McGranahan N, Lee WC, George J, Hu X, Chen Y, Wu M, Behrens C, Chow CW, Pham HHN, Fukuoka J, Wu J, Parra ER, Little LD, Gumbs C, Song X, Wu CJ, Diao L, Wang Q, Cardnell R, Zhang J, Wang J, Le X, Gibbons DL, Heymach JV, Jack Lee J, William WN, Cheng C, Glisson B, Wistuba I, Andrew Futreal P, Thomas RK, Reuben A, Byers LA, Zhang J. Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer. Nat Commun 12(1):6655, 2021. e-Pub 2021. PMID: 34789716.
- Wu J, Li C, Gensheimer M, Padda S, Kato F, Shirato H, Wei Y, Schönlieb CB, Price SJ, Jaffray D, Heymach J, Neal JW, Loo BW, Wakelee H, Diehn M, Li R. Radiological tumor classification across imaging modality and histology. Nat Mach Intell 3:787-798, 2021. e-Pub 2021. PMID: 34841195.
- Dejima H, Hu X, Chen R, Zhang J, Fujimoto J, Pa Drra ER, Haymaker C, Hubert SM, Duose D, Solis LM, Su, Fukuoka J, Tabata K, Pham HHN, Mcgranahan N, Zhang B, Ye J, Ying L, Little L, Gumbs C, Chow CW, Estecio MR, Godoy MCB, Antonoff MB, Sepesi B, Pass HI, Behrens C, Zhang J, Vaporciyan AA, Heymach JV, Scheet P, Lee JJ, Wu J, Futreal PA, Reuben A, Kadara H, Wistuba II, Zhang J. Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features. Nat Commun 12(1):2722, 2021. e-Pub 2021. PMID: 33976164.
- Jiang Y, Wang H, Wu J, Chen C, Yuan Q, Huang W, Li T, Xi S, Hu Y, Zhou Z, Xu Y, Li G, Li R. Noninvasive Imaging Evaluation of Tumor Immune Microenvironment to Predict Outcomes in Gastric Cancer. Ann Oncol 31(6):760-8, 2020. e-Pub 2020. PMID: 32240794.
- Zhang N, Wu J, Yu J, Zhu H, Yang M, Li R. Integrating Imaging, Histologic, and Genetic Features to Predict Tumor Mutation Burden of Non-Small-Cell Lung Cancer. Clin Lung Cancer 21(3):e151-e163, 2020. e-Pub 2020. PMID: 31734072.
- Wu J, Gensheimer MF, Zhang N, Guo M, Liang R, Zhang C, Fischbein N, Pollom EL, Beadle B, Le QT, Li R. Tumor Subregion Evolution-Based Imaging Features to Assess Early Response and Predict Prognosis in Oropharyngeal Cancer. J Nucl Med 61(3):327-336, 2020. e-Pub 2020. PMID: 31420498.
- Zhang N, Liang R, Gensheimer MF, Guo M, Zhu H, Yu J, Diehn M, Loo BW, Li R, Wu J. Early response evaluation using primary tumor and nodal imaging features to predict progression-free survival of locally advanced non-small cell lung cancer. Theranostics 10(25):11707-11718, 2020. e-Pub 2020. PMID: 33052242.
- Baek S, He Y, Allen BG, Buatti JM, Smith BJ, Tong L, Sun Z, Wu J, Diehn M, Loo BW, Plichta KA, Seyedin SN, Gannon M, Cabel KR, Kim Y, Wu X. Deep Segmentation Networks Predict Survival of Non-Small Cell Lung Cancer. Sci Rep 9(1):1-10, 2019. e-Pub 2019. PMID: 31754135.
- Wu J, Gensheimer MF, Zhang N, Han F, Liang R, Qian Y, Zhang C, Fischbein N, Pollom EL, Beadle B, Le QT, Li R. Integrating Tumor and Nodal Imaging Characteristics at Baseline and Mid-Treatment Computed Tomography Scans to Predict Distant Metastasis in Oropharyngeal Cancer Treated With Concurrent Chemoradiotherapy. Int J Radiat Oncol Biol Phys 104(4):942-952, 2019. e-Pub 2019. PMID: 30940529.
- Lee J, Li B, Cui Y, Sun X, Wu J, Zhu H, Yu J, Gensheimer MF, Loo BW, Diehn M, Li R. A Quantitative CT Imaging Signature Predicts Survival and Complements Established Prognosticators in Stage I Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 102(4):1098-1106, 2018. e-Pub 2018. PMID: 29439884.
- Wu J, Li X, Teng X, Rubin DL, Napel S, Daniel BL, Li R. MR Imaging and Molecular Features Associated with Tumor-Infiltrating Lymphocytes in Breast Cancer. Breast Cancer Res 20(1):101, 2018. e-Pub 2018. PMID: 30176944.
- Wu J, Cao G, Sun X, Lee J, Rubin DL, Napel S, Kurian AW, Daniel BL, Li R. Intratumoral Spatial Heterogeneity at Perfusion MR Imaging Predicts Recurrence-free Survival in Locally Advanced Breast Cancer Treated with Neoadjuvant Chemotherapy. Radiology 288(1):26-35, 2018. e-Pub 2018. PMID: 29714680.
- Qin W, Wu J, Han F, Yuan Y, Zhao W, Ibragimov B, Gu J, Xing L. Superpixel-Based and Boundary-Sensitive Convolutional Neural Network for Automated Liver Segmentation. Phys Med Biol 63(9):095017, 2018. e-Pub 2018. PMID: 29633960.
- Wu J, Tha KK, Xing L, Li R. Radiomics and Radiogenomics for Precision Radiotherapy. J Radiat Res 59(suppl_1):i25-i31, 2018. e-Pub 2018. PMID: 29385618.
- Lee J, Cui Y, Sun X, Li B, Wu J, Li D, Gensheimer MF, Loo BW, Diehn M, Li R. Prognostic Value and Molecular Correlates of a CT Image-Based Quantitative Pleural Contact Index in Early Stage NSCLC. Eur Radiol 28(2):736-746, 2018. e-Pub 2018. PMID: 28786009.
- Liu L, Li K, Qin W, Wen T, Li L, Wu J, Gu J. Automated Breast Tumor Detection and Segmentation with a Novel Computational Framework of Whole Ultrasound Images. Med Biol Eng Comput 56(2):183-199, 2018. e-Pub 2018. PMID: 29292471.
- Wu J, Li B, Sun X, Cao G, Rubin DL, Napel S, Ikeda DM, Kurian AW, Li R. Heterogeneous Enhancement Patterns of Tumor-adjacent Parenchyma at MR Imaging Are Associated with Dysregulated Signaling Pathways and Poor Survival in Breast Cancer. Radiology 285(2):401-413, 2017. e-Pub 2017. PMID: 28708462.
- Wu J, Sun X, Wang J, Cui Y, Kato F, Shirato H, Ikeda DM, Li R. Identifying Relations Between Imaging phenotypes and Molecular Subtypes of Breast Cancer: Model Discovery and External Validation. J Magn Reson Imaging 46(4):1017-1027, 2017. e-Pub 2017. PMID: 28177554.
- Cui Y, Ren S, Tha KK, Wu J, Shirato H, Li R. Volume of High-Risk Intratumoral Subregions at Multi-Parametric MR Imaging Predicts Overall Survival and Complements Molecular Analysis of Glioblastoma. Eur Radiol 27(9):3583-3592, 2017. e-Pub 2017. PMID: 28168370.
- Wu J, Cui Y, Sun X, Cao G, Li B, Ikeda DM, Kurian AW, Li R. Unsupervised Clustering of Quantitative Image Phenotypes Reveals Breast Cancer Subtypes with Distinct Prognoses and Molecular Pathways. Clin Cancer Res 23(13):3334-3342, 2017. e-Pub 2017. PMID: 28073839.
- Wu J, Simon MA, Brigham JC. A Comparison of Global Shape Analysis Methods for the Assessment of Right Ventricular Function. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization 4(6):327-343, 2016. e-Pub 2016.
- Wu J, Gong G, Cui Y, Li R. Intratumor Partitioning and Texture Analysis of Dynamic Contrast-Enhanced (DCE)-MRI Identifies Relevant Tumor Subregions to Predict Pathological Response of Breast Cancer to Neoadjuvant Chemotherapy. J Magn Reson Imaging 44(5):1107-1115, 2016. e-Pub 2016. PMID: 27080586.
- Wu J, Aguilera T, Shultz D, Gudur M, Rubin DL, Loo BW, Diehn M, Li R. Early-Stage Non-Small Cell Lung Cancer: Quantitative Imaging Characteristics of (18)F Fluorodeoxyglucose PET/CT Allow Prediction of Distant Metastasis. Radiology 281(1):270-8, 2016. e-Pub 2016. PMID: 27046074.
- Wu J, Gensheimer MF, Dong X, Rubin DL, Napel S, Diehn M, Loo BW, Li R. Robust Intratumor Partitioning to Identify High-Risk Subregions in Lung Cancer: A Pilot Study. Int J Radiat Oncol Biol Phys 95(5):1504-1512, 2016. e-Pub 2016. PMID: 27212196.
- Wu J, Brigham KG, Simon MA, Brigham JC. An Implementation of Independent Component Analysis for 3D Statistical Shape Analysis. Biomedical Signal Processing and Control 13(5):345-356, 2014. e-Pub 2014.
- Wu J, Wang, Y, Simon, MA, Sacks, MS, Brigham JC. A New Computational Framework for Anatomically Consistent 3D Statistical Shape Analysis with Clinical Imaging Applications. Computer Methods in Biomechanics and Biomedical Engineering: Imaging and Visualization 1(1):13-27, 2013. e-Pub 2013.
- Wu J, Wang Y, Simon MA, Brigham JC. A New Approach to Kinematic Feature Extraction from the Human Right Ventricle for Classification of Hypertension: a Feasibility Study. Phys Med Biol 57(23):7905-22, 2012. e-Pub 2012. PMID: 23154583.
- Aminu§ M, Daver N, Godoy MC, Shroff G, Wu C, Torre-Sada LF, Goizueta A, Shannon VR, Faiz SA, Altan M, Garcia-Manero G, Kantarjian H, Ravandi-Kashani F, Kadia T, Konopleva M, DiNardo C, Pierce S, Naing A, Kim ST, Kontoyiannis DP, Khawaja F, Chung C, Wu J. Heterogenous lung inflammation CT patterns distinguish pneumonia and immune checkpoint inhibitor pneumonitis and complement blood biomarkers in acute myeloid leukemia: proof of concept. Frontiers in Immunology.
- Chen P, Rojas F, Hu X, Serrano A, Zhu B, Chen H, Hong L, Bandyoyadhyay R, Aminu M, Kalhor N, Hussein SE, Cannatella J, Khoury JD, Pass HI, Moreira AL, Fukuoka J, Tabata K, Su D, Ying L, Gibbons DL, Heymach JV, Wistuba II, Fujimoto J, Solis Soto LM, Zhang J, Wu J. Pathomic Features Reveal Immune and Molecular Evolution from Lung Preneoplasia to Invasive Adenocarcinoma. Mod Path.
- Vokes NI, Galan-Cobo A, Fernandez-Chas M, Molkentine DP, Treviño S, Druker V, Qian Y, Patel SA, Schmidt S, Hong L, Lewis J, Rinsurongkawong W, Rinsurongkawong V, J Jack Lee J, Negrao MV, Gibbons DL, Vaporciyan AA, Le X, Wu J, Zhang J, Rigney UA, Iyer S, Dean E, Heymach JV. ATM mutations associate with distinct co-mutational patterns and therapeutic vulnerabilities in NSCLC. Clinical Cancer Research.
Other Articles
- Reddy DR, Cuenca JA, Botdorf J, Muthu M, Hanmandlu A, Wegner R, Crommett J, Gutierrez C, Rathi N, Sajith B, Knafl M, Collaborators DT Clinical Characteristics and Cause of Death Among Hospitalized Decedents with Cancer and COVID-19. Mayo Clinic Proceedings 98(3):451-457, 2023. PMID: 36868753.
- Tariq U, Qureshi R, Zafar A, Aftab D, Wu J, Alam T, Shah Z, Ali H Brain Tumor Synthetic Data Generation with Adaptive StyleGANs. In Artificial Intelligence and Cognitive Science: 30th Irish Conference, AICS 2022 Munster, Ireland, December 8–9, 2022, Revised Selected Papers:147-159, 2023.
- Qureshi, Rizwan, Alam T, Wu AJ Drug response prediction for lung cancer patients using biophysical simulation and machine learning. 2022 IEEE International Conference on Bioinformatics and Biomedicine (BIBM), 2022.
- Chen P, Saad MB, Rojas FR, Salehjahromi M, Aminu M, Bandyopadhyay R, Hong L, Ebare K, Behrens C, Gibbons DL, Kalhor N, Heymach JV, Wistuba II, Solis Soto LM, Zhang J, Wu J Cellular Architecture on Whole Slide Images Allows the Prediction of Survival in Lung Adenocarcinoma. International Workshop on Computational Mathematics Modeling in Cancer Analysis, 2022.
- Rohail, Kinza, Bashir S, Ali H, Alam T, Khan S, Wu J, Chen§ P, Qureshi AR Understanding Tumor Micro Environment using Graph theory. Proceedings of the Asian Conference on Computer Vision, 2022.
- Bandyopadhyay R, Chen P, Hussein SE, Rojas FR, Ebare K, Wistuba II, Solis Soto LM, L Jeffrey Medeiros L, Zhang J, Khoury JD, Wu J Is More Always Better? Effects of Patch Sampling in Distinguishing Chronic Lymphocytic Leukemia from Transformation to Diffuse Large B-Cell Lymphoma. International Workshop on Computational Mathematics Modeling in Cancer Analysis, 2022.
- Bai, X, Wang, H, Ma, L, Xu, Y, Gan, J, Fan, Z, Yang, F, Ma, K, Yang, J, Bai, S, Shu, C, Zou, X, Huang, R, Zhang, C, Liu, X, Tu, D, Xu, C, Zhang, W, Wang, X, Chen, A, Zeng, Y, Yang, D, Wang, MW, Holalkere, NS, Halin, NJ, Kamel, IR, Wu, J, Peng, X, Wang, X, Shao, J, Mongkolwat, P, Zhang, J, Liu, W, Roberts, M, Teng, Z, Beer, L, Sanchez, LE, Sala, E, Rubin, D, Weller, A, Lasenby, J, Zheng, C, Wang, J, Li, Z, Schönlieb, CB, Xia, T Author Correction. Nature Machine Intelligence 4(4):413, 2022. PMID: 37520117.
- Chen P, Aminu M, El Hussein S, Khoury JD, Wu, J CellSpatialGraph: Integrate hierarchical phenotyping and graph modeling to characterize spatial architecture in tumor microenvironment on digital pathology. Software Impacts 10, 2021.
- Chen, P, Aminu, M, Hussein E, S, Khoury, JD, Wu, J Hierarchical phenotyping and graph modeling of spatial architecture in lymphoid neoplasms. International Conference on Medical Image Computing and Computer-Assisted Intervention (MICCAI), 2021.
- Jiang, YM, Wang, H, Wu, J, Chen, C, Yuan, Q, Huang, W, Li, T, Xi, S, Hu, Y, Zhou, Z, Xu, Y, Li, GX, Li, R Corrigendum to “Noninvasive imaging evaluation of tumor immune microenvironment to predict outcomes in gastric cancer” (Annals of Oncology (2020) 31(6) (760–768), (S0923753420363821), (10.1016/j.annonc.2020.03.295)). Annals of Oncology 32(4):578, 2021. PMID: 33546918.
- Yu N, Wu J, Weinstein SP, Gaonkar B, Keller BM, Ashraf AB, Jiang Y, Davatzikos C, Conant EF, Kontos D A superpixel-based framework for automatic tumor segmentation on breast DCE-MRI. SPIE Medical Imaging 2015: Computer-Aided Diagnosis 9414:172-178, 2015.
- Wu J, Ou Y, Weinstein SP, Conant EF, Yu N, Hoshmand V, Keller B, Ashraf AB, Rosen M, DeMichele A, Davatzikos C Quantification of tumor changes during neoadjuvant chemotherapy with longitudinal breast DCE-MRI registration. SPIE Medical Imaging 2015: Computer-Aided Diagnosis 9414:502-508, 2015.
Editorials
- Wu, J, Qin, W, Li, C, Kim, B. Preface. Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) 15181 LNCS:v, 2025.
- Qin, W, Zhang, F, Yang, F, Zaki, N, Wu, J, Li, C. Preface. Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) 14243 LNCS:v-vii, 2023.
- Zhao, W, Zhang, Y, Wu, J, Li, X, Jiang, YM. Editorial. Frontiers in Oncology 12, 2022. PMID: 36263205.
- Qin, W, Zaki, N, Zhang, F, Wu, J, Yang, F. Preface. Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) 13574 LNCS:v-vi, 2022.
- Zhao W, Zhang Y, Wu J, Li X, Jiang Y. Machine learning in radiation oncology. Frontiers in Oncology 12, 2022.
Abstracts
- Chen H, Zhu B, Fujimoto J, Tian Y, Li J, Chen P, Reuben A, Nilsson MB, Le X, Poteete A, Hubert SM, Gibbons DL, Wistuba II, Wu J, Cheng C, Heymach JV, Zhang J. Single-cell transcriptomic analysis reveals immune landscape in the malignant transformation of normal lung to lung adenocarcinoma in genetic murine models. Cancer Research 83(7_Supplement):6524-6524, 2023. e-Pub 2023.
- Deboever N, Al-Tashi Q, Eisenberg M, Hofstetter W, Mehran R, Rice D, Roth J, Sepesi B, Swisher S, Vaporciyan A, Walsh G, Antonoff M, Wu J, Rajaram R. Machine learning prediction of financial toxicity in patients with resected lung cancer. Cancer Research 83(7_Supplement):726-726, 2023. e-Pub 2023.
- Li C, Nguyen TT, Li JR, Song X, Wistuba II, Futureal A, Zhang J, Hubert SM, Wu J, Zhang J, Cheng C. Multiregional profiling revealed intra-tumor transcriptomic heterogeneity associated with the prognosis in non-small cell lung cancer. Cancer Research 83(7_Supplement):97-97, 2023. e-Pub 2023.
- Chen P, Rojas F, Hu X, Fujimoto J, Serrano A, Zhu B, Hong L, Bandyopadhyay R, Aminu M, Saad MB, Salehjahromi M, Sujit SJ, Kalhor N, Pass HI, Moreira AL, Wistuba II, Gibbons DL, Heymach JV, Solis Soto LM, Zhang J, Wu J. Pathomics reveals the molecular and immune evolution from lung preneoplasia to invasive adenocarcinoma. Cancer Research 83(7_Supplement):5443-5443, 2023. e-Pub 2023.
- Aminu M, Vokes NI, Saad MB, Li H, Hong L, Mohamed MS, Boom J, Chen P, Altan M, Gandhi S, Swisher S, Antonoff MB, Pozadzides JV, Jr GB, Gibbons DL, Cascone T, Elamin YY, Le X, Negrao MV, Skoulidis F, Tsao AS, Tu J, J Jack Lee J, Zhang J, Heymach JV, Wu J. Tumor volumetric analysis to correlate disease burden with response to dual immune checkpoint blockade in metastatic NSCLC. Cancer Research 83(7_Supplement):4393-4393, 2023. e-Pub 2023.
- Hong L, Aminu M, Lu X, Saad MB, Chen P, Rinsurongkawong W, Spelman A, Elamin YY, Negrao MV, Skoulidis F, Gay CM, Cascone T, Antonoff MB, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Le X, J Jack Lee J, Roy-Chowdhuri S, Routbort MJ, Heymach JV, Wu J, Zhang J, Vokes NI. Genomic and clinical predictors of early disease progression and chemoimmunotherapy benefit in advanced NSCLC. Cancer Research 83(7_Supplement):964-964, 2023. e-Pub 2023.
- Zhu B, Li J, Chen H, Chen P, Fujimoto J, Tian Y, Aminu M, Li C, Hong L, Reuben A, Parra Cuentas ER, Shi O, Nilsson M, Poteete A, Hubert S, Khan K, Lu W, Kraushaar D, Song X, Zhang J, Gibbons D, Soto LS, Wistuba I, Wu J, Heymach J, Cheng C, Zhang J. Single cell and spatial profiling reveal molecular and immune evolution from precancers to invasive lung adenocarcinomas in genetic and carcinogen-induced mouse models. Cancer Research 83(7_Supplement):6513-6513, 2023. e-Pub 2023.
- El Hussein S, Chen P, Salehjahromi M, Fang H, Wang W, Loghavi S, Reagan PM, Friedberg JW, Burack R, Evans AG, Medeiros LJ, Wu J, Khoury JD. Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence. Blood 140(Supplement 1):7836-7, 2022. e-Pub 2022.
- Saad MB, Hong L, Aminu M, Vokes NI, Chen P, Wu CC, Rinsurongkawong W, Spelman AR, Negrao MV, Cascone T, Lin SH, Lee P, Sepesi B, Gibbons DL, Vaporciyan AA, Lee J, Le X, Zhang J, Wu J, Heymach J. Deep learning signature from chest CT and association with immunotherapy outcomes in EGFR/ALK-negative NSCLC. Journal of Clinical Oncology 40, no. 16_suppl:9061-9061, 2022. e-Pub 2022.
- Hong L, Rinsurongkawong W, Saad MB, Chen P, Aminu M, Spelman AR, Negrao MV, Cascone T, Lin SH, Lee P, Sepesi B, Lewis J, Gibbons DL, Vaporciyan AA, Lee J, Le X, Wu J, Heymach J, Zhang J, Vokes NI. Real-world effectiveness of immune checkpoint inhibitors alone or in combination with chemotherapy in metastatic non–small cell lung cancer. Journal of Clinical Oncology 40, no. 16_suppl:9055-9055, 2022. e-Pub 2022.
- S El Hussein S, P Chen P, J Boom J, I Wistuba I, LJ Medeiros LJ, J Wu J, J Khoury J. Proliferation Center-Focused Artificial Intelligence Algorithm Enhances Detection of Accelerated Phase Chronic Lymphocytic Leukemia. Laboratory Investigation 102 (SUPPL 1):939-941, 2022. e-Pub 2022.
- El Hussein S, Chen P, Medeiros LJ, Wu J, Khoury JD. Artificial Intelligence-Assisted Mapping of Proliferation Centers in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Identifies Patterns That Reliably Distinguish Accelerated Phase and Large Cell Transformation. Blood(138):1558, 2021. e-Pub 2021.
- Chen P, Elhussein S, Medeiros LJ, Khoury JD, Wu J. Machine Learning Pipeline with Feature Engineering Provides Robust Diagnostic Predictions in Chronic Lymphocytic Leukemia, Accelerated and Transformed Phases. Blood(138):3738, 2021. e-Pub 2021.
- Zhang N, Wu J, Yang M, Yu J, Li R. A composite model integrating imaging, histological, and genetic features to predict tumor mutation burden in non-small cell lung cancer patients. International Journal of Radiation Oncology, Biology, Physics 105(1):E541, 2019. e-Pub 2019.
- Wu J, Gensheimer M, Liang R, Zhang C, Pollom E, Beadle BM, Le QT, Li R. Habitat Evolution Imaging Biomarkers to Assess Early Response and Predict Treatment Outcomes in Oropharyngeal Cancer. International Journal of Radiation Oncology• Biology• Physics 105(1):S32, 2019. e-Pub 2019.
- Wu J, Gensheimer MF, Dong X, Rubin DL, Napel S, Diehn M, Loo BW, Li R. Intratumor Partitioning of Serial Computed Tomography and FDG Positron Emission Tomography Images Identifies High-Risk Tumor Subregions and Predicts Patterns of Failure in Non-Small Cell Lung Cancer After Radiation Therapy. International Journal of Radiation Oncology, Biology, Physics 96(2):S100, 2016. e-Pub 2016.
Book Chapters
- Al Tashi, Q, Mirjalili, S, Wu, J, Abdulkadir, SJ, Shami, TM. Moth-Flame Optimization Algorithm for Feature Selection, 11-34, 2022.
- Al-Tashi, Qasem, Mirjalili S, Wu J, Abdulkadir SJ, Shami TM, Khodadadi N, Alqushaibi AA. Moth-flame optimization algorithm for feature selection: A review and future trends. In: Handbook of Moth-Flame Optimization Algorithm, 2022.
- Liu Y, Zhang S, Yang X, Wu J, Li C. Distance Regularized Level Sets for Segmentation of the Left and Fight Ventricles, in Biomedical Image Segmentation. In: Advances and Trends, 347-370, 2016.
- Wu, J, Brigham, JC. Computational Techniques for Analysis of Organ-Level Shape and Kinematics. In: Image-based Geometric Modeling and Mesh Generation, 2013.
Letters to the Editor
- Li, J, Shaw, VR, Lin, Y, Wang, X, Aminu, M, Li, Y, Wu, J, Zhang, J, Amos, CI, Cheng, C. The prognostic effect of infiltrating immune cells is shaped by proximal M2 macrophages in lung adenocarcinoma. Molecular cancer 23, 2024.
Selected Presentations & Talks
Local Presentations
- 2023. Empower Digital Pathology with Machine Learning and Usher It into Multi-Modal Integration. Conference. Empower Digital Pathology with Machine Learning and Usher It into Multi-Modal Integration, US.
Regional Presentations
- 2023. The Beginning of the End for RECIST, and Moving Toward 3D Volumetric-Based Whole-Body Response with Its Application in Personalized Immunotherapy. Conference. The Beginning of the End for RECIST, and Moving Toward 3D Volumetric-Based Whole-Body Response with Its Application in Personalized Immunotherapy, US.
- 2023. Habitat Imaging Phenotypes Identify Tumor Molecular Programs and Patterns of Clinical and Circulating Disease Recurrence in Early-Stage Non-Small Cell Lung Cancer. Conference. Habitat Imaging Phenotypes Identify Tumor Molecular Programs and Patterns of Clinical and Circulating Disease Recurrence in Early-Stage Non-Small Cell Lung Cancer, US.
- 2023. Habitat Imaging Analysis: Application in COVID-19, Lung Cancer, Immunotherapy Toxicity. Conference. Habitat Imaging Analysis: Application in COVID-19, Lung Cancer, Immunotherapy Toxicity, US.
- 2023. STRIDE (STrategic Research Initiative DEvelopment) Research Town Hall -- Tumor Measurement Initiative. Conference. STRIDE (STrategic Research Initiative DEvelopment) Research Town Hall -- Tumor Measurement Initiative, US.
- 2023. Machine Learning to Augment Lung Cancer Screening. Conference. Machine Learning to Augment Lung Cancer Screening, US.
- 2022. Lung Cancer Analytics Platform. Conference. Lung Cancer Analytics Platform, US.
- 2022. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19. Conference. Habitat Imaging Biomarkers for Diagnosis and Prognosis in Cancer Patients Infected with COVID-19, US.
- 2022. Deep Learning of CT Predicts Benefit to Immunotherapy in Lung Cancer. Conference. Deep Learning of CT Predicts Benefit to Immunotherapy in Lung Cancer, US.
- 2022. Integrate imaging and Biospecimen-Derived Assays to Decipher Tumor Microenvironment in the Era of Immunotherapy. Conference. Integrate imaging and Biospecimen-Derived Assays to Decipher Tumor Microenvironment in the Era of Immunotherapy, US.
- 2021. Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy. Conference. Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy, US.
- 2021. Habitat Imaging Analysis of Lung Cancer. Conference. Habitat Imaging Analysis of Lung Cancer, US.
- 2020. Artificial Intelligence 101 in Medical Imaging: Open the Door to Discover Clinically Meaningful Imaging Markers in Precision Oncology. Conference. Artificial Intelligence 101 in Medical Imaging: Open the Door to Discover Clinically Meaningful Imaging Markers in Precision Oncology, US.
National Presentations
- 2025. AI and Multi-modal Modeling in Lung Cancer,. Invited. Gilbert W. Beebe Symposium on AI and ML Applications in Radiation Therapy, Medical Diagnostics, and Radiation Occupational Health and Safety. Washington, D.C, US.
- 2025. Advancing Clinical Trials: Radiomics and Multiscale Machine Learning for Patient Selection and Stratification. Invited. NRG Developmental Therapeutics/Radiation Oncology Meeting. Phoenix, AZ, US.
- 2024. Harnessing AI for Enhanced Molecular Imaging in Cancer Research. Invited. Montreal, CA.
- 2024. Radiomics and Artificial Intelligence for Precision Oncology. Invited, US.
- 2024. he World Molecular Imaging Congress. Invited. Naples, IT.
- 2024. AI in Clinical Risk Prediction. Invited. Dallas, Texas, US.
- 2023. Keynote Speaker: Multi-modal Integration and Modeling to Advance Precision Oncology. Conference. Keynote Speaker: Multi-modal Integration and Modeling to Advance Precision Oncology, US.
- 2023. Machine learning to analyze radiographic scans and digital pathology slides and integrate genomic data. Conference. Machine learning to analyze radiographic scans and digital pathology slides and integrate genomic data, US.
- 2023. Using large language models to predict clinical trial success. Conference. Using large language models to predict clinical trial success, US.
- 2023. Artificial Intelligence to Surpass Radiomics with Multi-Platform Integration for Precision Oncology. Conference. Artificial Intelligence to Surpass Radiomics with Multi-Platform Integration for Precision Oncology, US.
- 2022. Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence. Conference. Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence. New Orleans, LA, US.
- 2022. Integrated Imaging and Molecular Analysis to Decipher Tumor Microenvironment in the Era of Immunotherapy. Conference. The 2nd MD Anderson Cancer Center and ShangHai Concord Cancer Center Annual International Academic Meeting, US.
- 2022. Proliferation Center-Focused Artificial Intelligence Algorithm Enhances Detection of Accelerated Phase Chronic Lymphocytic Leukemia. Conference. Proliferation Center-Focused Artificial Intelligence Algorithm Enhances Detection of Accelerated Phase Chronic Lymphocytic Leukemia. Los Angeles, CA, US.
- 2021. Artificial Intelligence-Assisted Mapping of Proliferation Centers in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Identifies Patterns That Reliably Distinguish Accelerated Phase and Large Cell Transformation. Conference. Artificial Intelligence-Assisted Mapping of Proliferation Centers in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Identifies Patterns That Reliably Distinguish Accelerated Phase and Large Cell Transformation. Atlanta, GA, US.
- 2021. Machine Learning Pipeline with Feature Engineering Provides Robust Diagnostic Predictions in Chronic Lymphocytic Leukemia, Accelerated and Transformed Phases. Conference. Machine Learning Pipeline with Feature Engineering Provides Robust Diagnostic Predictions in Chronic Lymphocytic Leukemia, Accelerated and Transformed Phases. Atlanta, GA, US.
- 2021. Spearhead Clinically Relevant Radiologic Biomarker Discovery in Precision Oncology with Habitat Imaging, Virtual Symposium and Scientific Meeting. Conference. Virtual Symposium and Scientific Meeting, US.
- 2018. Quantitative DCE-MRI Features Can Complement Molecular Markers for Predicting Tumor Infiltrating Lymphocytes in Breast Cancer: Model Discovery and Independent Validation. Conference. Quantitative DCE-MRI Features Can Complement Molecular Markers for Predicting Tumor Infiltrating Lymphocytes in Breast Cancer: Model Discovery and Independent Validation. Chicago, IL, US.
- 2016. Intratumor Partitioning of Serial CT and FDG-PET Images Identifies High-risk Tumor Subregions and Predicts Patterns of Failure in Non-small Cell Lung Cancer After Radiotherapy. Conference. Intratumor Partitioning of Serial CT and FDG-PET Images Identifies High-risk Tumor Subregions and Predicts Patterns of Failure in Non-small Cell Lung Cancer After Radiotherapy. Boston, MA, US.
- 2015. Tumor Heterogeneity Patterns of DCE-MRI Parametric Response Maps May Augment Early Assessment of Neoadjuvant Chemotherapy: A Pilot Study of ACRIN 6657/I-SPY 1. Conference. Tumor Heterogeneity Patterns of DCE-MRI Parametric Response Maps May Augment Early Assessment of Neoadjuvant Chemotherapy: A Pilot Study of ACRIN 6657/I-SPY 1. Chicago, IL, US.
- 2014. A Feasibility Study Investigating the Use of Quantitative Measures of Spatio-temporal Tumor Heterogeneity Derived from 4D Breast Page 4 of 6 DCE-MRI Registration as a Biomarker of Response to Neoadjuvant Chemotherapy. Conference. A Feasibility Study Investigating the Use of Quantitative Measures of Spatio-temporal Tumor Heterogeneity Derived from 4D Breast Page 4 of 6 DCE-MRI Registration as a Biomarker of Response to Neoadjuvant Chemotherapy. Austin, TX, US.
- 2014. A feasibility study on kinematic feature extraction from the human interventricular septum toward hypertension classification. Conference. A feasibility study on kinematic feature extraction from the human interventricular septum toward hypertension classification. Pittsburgh, PA, US.
- 2013. An Investigation of Shape Analysis Methods for Assessment of Organ-Level Functional Changes in the Human Right Ventricle. Conference. An Investigation of Shape Analysis Methods for Assessment of Organ-Level Functional Changes in the Human Right Ventricle. Raleigh, NC, US.
- 2011. Geometric Analysis and Decomposition of Normal and Hypertensive Human Right Ventricle from Diagnostic Medical Imaging. Conference. Geometric Analysis and Decomposition of Normal and Hypertensive Human Right Ventricle from Diagnostic Medical Imaging. Pittsburgh, PA, US.
Formal Peers
- 2022. AI Bridge Radiology and Pathology. Invited, US.
- 2021. Integrated imaging and molecular analysis to decipher tumor microenvironment in the era of immunotherapy. Invited. Austin, TX, US.
- 2020. Habitat Imaging for COVID-19: Discover Clinically Relevant and Actionable Biomarkers. Invited, US.
- 2019. Empower Radiology with Artificial Intelligence: Discover Clinically Relevant and Actionable Imaging Markers. Invited. Stanford, CA, US.
- 2019. Artificial Intelligence in Radiology: Discover Clinically Relevant & Actionable Imaging Markers, Department of Radiology. Invited. New York, NY, US.
- 2019. Discover Clinically Relevant and Actionable Imaging Markers with Artificial Intelligence, Radiology Research Grand Round. Invited. Los Angeles, CA, US.
- 2018. Artificial Intelligence in Medical Imaging: Converting Pictures into Clinically Useful Information for Precision Medicine. Invited. Atlanta, GA, US.
- 2018. Artificial Intelligence in Radiology: Discover Clinically Relevant and Actionable Imaging Markers in Precision Oncology. Invited. New York City, NY, US.
- 2018. Unraveling Tumor Heterogeneity Using Artificial Intelligence: Radiomics, Radiogenomics and Habitat Imaging, Center for Biomedical Informatics. Invited. Winston-Salem, NC, US.
- 2018. Spearhead Clinically Relevant Radiologic Biomarker Discovery in Precision Oncology with Artificial Intelligence. Invited. New York City, NY, US.
- 2017. Radiomic and Radiogenomic Analysis for Clinically Relevant Imaging Biomarkers in Precision Oncology, Radiology Grand Rounds & Translational Research Seminar. Invited. Danville, PA, US.
- 2013. Computational Statistical Shape Analysis of Medical Images for Hypertension Classification. Invited. Saint Louis, MO, US.
Grant & Contract Support
| Date: | 2026 - 2030 |
| Title: | Development of new electronic health records (EHR)-agnostic clinical decision support tools to assess cardiovascular disease risk in breast cancer patients |
| Funding Source: | Department of Defense (DOD) |
| Role: | Co-PI |
| ID: | PR251003 |
| Date: | 2026 - 2028 |
| Title: | Developing Spatial Machine Learning Algorithms and an AI Copilot for Early Interception of Lung Precancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | Career Guide |
| ID: | CA251414 |
| Date: | 2026 - 2026 |
| Title: | Lung-AIR: Lung Cancer Risks Prediction by Artificial Intelligence-enhanced Radiomics-blood Biomarkers to Guide Future Personalized Lung Precancer Interception |
| Funding Source: | The University of Texas Foundation |
| Role: | Co-PI |
| Date: | 2025 - 2029 |
| Title: | Decoding Lung Precancer Progression Through Integrated Multiscale Modeling |
| Funding Source: | Cancer Prevention Research Institute of Texas instead of just CPRIT |
| Role: | Multi PI |
| ID: | RP260435 |
| Date: | 2025 - 2030 |
| Title: | A Multi-Scale Computational Approach in Spatial Biology to Understand Lung Carcinogenesis Evolution for Effective Cancer Prevention |
| Funding Source: | NIH |
| Role: | Mentor |
| ID: | 1K99CA308926-01 |
| Date: | 2025 - 2032 |
| Title: | Unleashing Innate Immune Response to Boost Anti-tumor Immunity against Brain Metastasis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R35CA293986-01A1 |
| Date: | 2025 - 2026 |
| Title: | Predicting tarlatamab intracranial response and resistance through radiomics and liquid biopsies in patients with small cell lung cancer |
| Funding Source: | Andrew M. McDougall Brain Metastasis Clinic and Research Program |
| Role: | PI |
| Date: | 2025 - 2026 |
| Title: | Catalyzing a Cure for Oncogene Addicted Lung Cancers |
| Funding Source: | Break Through Cancer Foundation |
| Role: | Project Leader |
| Date: | 2025 - 2030 |
| Title: | (P50 Renewal) SPORE: Targeting Lung Cancer Vulnerabilities |
| Funding Source: | Un of Tx Southwestern Med Ctr - Dallas |
| Role: | Co Leade |
| Date: | 2025 - 2028 |
| Title: | RAID-Lung Cancer: Rapid AI-Integrated Diagnosis of Lung CancerNSCLC Patients Receiving SABR and Immunotherapy |
| Funding Source: | Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation |
| Role: | Co-I |
| Date: | 2025 - 2030 |
| Title: | Personalized Cardio-Oncology through Blood and Digital Biomarker Monitoring of Cardiovascular Risk in Thoracic Radiotherapy |
| Funding Source: | NIH/NCI-sub through Massachusetts General Hospital |
| Role: | Multi-Principal Investigator |
| Date: | 2025 - 2028 |
| Title: | To develop and validate personalized cardiovascular point-of-care tools for female breast cancer patients using precision medicine and AI/ML approaches |
| Funding Source: | University of Texas – Southwest Medical Center |
| Role: | PI |
| ID: | 1R01HL180971-01 |
| Date: | 2025 - 2026 |
| Title: | Leveraging Blood Epigenomic Signatures and Sociodemographic Determinants to Predict Outcomes in NSCLC Patients Receiving SABR and Immunotherapy |
| Funding Source: | AMERICAN SOC FOR RADIATION ONC (ASTRO) |
| Role: | Co-Mentor |
| Date: | 2025 - 2030 |
| Title: | Determining Myeloid Cell Spatiotemporal Mechanisms of Response and Resistance to Immunotherapy |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA303953-01 |
| Date: | 2025 - 2032 |
| Title: | Novel approaches to targeting therapeutic resistance in oncogene-driven NSCLC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R35CA305297-01 |
| Date: | 2025 - 2030 |
| Title: | Clinical and radiomic tools linking interstitial lung disease risk markers to immune checkpoint inhibitor pneumonitis |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA303013-01 |
| Date: | 2025 - 2030 |
| Title: | Integration of radiomic and circulating cell-free DNA methylation signatures in early detection of HPV-positive oropharyngeal cancer recurrence after initial treatment |
| Funding Source: | NIH |
| Role: | PI |
| ID: | 1R01DE034605-01A1 |
| Date: | 2025 - 2027 |
| Title: | AI-powered Multiscale Digital Twin to Personalize Immunotherapy |
| Funding Source: | The Andrew Sabin Family Foundation |
| Role: | PI |
| Date: | 2025 - 2030 |
| Title: | A Multiscale Modeling to Delineate the Evolution from Precancer to Invasive Lung Adenocarcinoma |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA303142-01 |
| Date: | 2025 - 2030 |
| Title: | Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA303046-01 |
| Date: | 2025 - 2028 |
| Title: | Forecasting Cancer Risk for Patient Stratification in Cancer Interception Trials using Liquid Biopsies and Bronchoscopy |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | LC240326 |
| Date: | 2025 - 2030 |
| Title: | Reprogram innate immunity for lung cancer immunoprevention |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | UG3CA290311 |
| Date: | 2025 - 2026 |
| Title: | 22nd IEEE International Symposium on Biomedical Imaging (ISBI 2025) |
| Funding Source: | NIH/NBIB |
| Role: | PI |
| ID: | 1R13EB037423-01 |
| Date: | 2025 - 2028 |
| Title: | Dissecting mechanisms of resistance to immune checkpoint blockade in NSCLC through the interplay of molecular and spatial architecture |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP250399 |
| Date: | 2025 - 2026 |
| Title: | MD Anderson Cancer Immune Monitoring and Analysis Center MDA-CIMAC |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5U24CA224285-03 |
| Date: | 2025 - 2029 |
| Title: | Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP250156 |
| Date: | 2025 - 2025 |
| Title: | Intercept lung adenocarcinoma precursors by anti-TIM3 for lung cancer prevention |
| Funding Source: | UTMDACC Lung SPORE Development Research |
| Role: | Co-PI |
| Date: | 2025 - 2028 |
| Title: | Prediction and treatment of brain and leptomeningeal metastatic disease in EGFR-mutant NSCLC |
| Funding Source: | UTMDACC Lung SPORE Development Research |
| Role: | Co-PI |
| Date: | 2024 - 2028 |
| Title: | Novel therapeutic strategies for evaluating and targeting minimal residual disease (MRD) and drug resistance in oncogene-driven NSCLC |
| Funding Source: | LUNG CANCER RESEARCH FOUNDATION |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Clinical-radiomic machine learning model predicts progression after RET TKI |
| Funding Source: | Lungevity Foundation |
| Role: | PI |
| Date: | 2024 - 2030 |
| Title: | BEGIN BATTLE: integrated biomarker-guided approaches for therapy selection, tailored early intensification, and targeting resistance mechanisms in lung cancer |
| Funding Source: | Advanced Research Projects Agency for Health |
| Role: | PI |
| Date: | 2024 - 2025 |
| Title: | Catalyzing a Cure for Oncogene Addicted Lung Cancers- Project Zero |
| Funding Source: | Break Through Cancer Foundation |
| Role: | Co-I |
| ID: | AWD00008768 |
| Date: | 2024 - 2025 |
| Title: | CCSG Administrative Supplement to Establish a Consortium of Cancer Centers that participate in a single, Nationwide, Privacy-Preserving, Reusable Federated Learning Network |
| Funding Source: | NCI |
| Role: | Project Leader |
| Date: | 2024 - 2029 |
| Title: | Imaging Innovation for Head And Neck Cancer Evaluation & Treatment Delivery |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1P01CA278716-01A1 |
| Date: | 2024 - 2029 |
| Title: | Integrating Computational and Experimental Techniques for Biomarker Discovery in Lung Adenocarcinoma |
| Funding Source: | Baylor College of Medicine |
| Role: | PI |
| Date: | 2024 - 2029 |
| Title: | Precision Lung Cancer Interception by Targeting High-Risk Lung Nodules |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | RP240441 |
| Date: | 2024 - 2025 |
| Title: | 3rd Workshop on Computational Mathematics Modeling in Cancer Analysis |
| Funding Source: | NIH |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Bridging Precision Medicine with Immunotherapy in Early-stage NSCLC: A Machine Learning Radiomics Framework on Phase II I-SABR Trial |
| Funding Source: | The University of Texas Foundation |
| Role: | PI |
| Date: | 2024 - 2026 |
| Title: | Defining mediators of response and resistance to single vs combination immunotherapy in NSCLC |
| Funding Source: | A Breath of Hope Lung Foundation |
| Role: | PI |
| Date: | 2024 - 2029 |
| Title: | Integration of radiomic and circulating cell-free DNA methylation signatures in early detection of HPV-positive oropharyngeal cancer recurrence after initial treatment |
| Funding Source: | NIH/NIDCR |
| Role: | Multiple Principal Investigator |
| ID: | 1R01DE033895-01 |
| Date: | 2024 - 2027 |
| Title: | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP240117 |
| Date: | 2024 - 2027 |
| Title: | Novel high-throughput approaches to identifying transcriptional and genomic mechanisms of resistance to 1st and 2nd-gen RET TKIs |
| Funding Source: | NIH |
| Role: | Collaborator |
| ID: | 1R35CA305297-01 |
| Date: | 2024 - 2029 |
| Title: | Serum cell-free DNA methylation and radiomics signatures for the early detection of recurrence after initial treatment in HPV-associated oropharyngeal cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Co-I |
| ID: | RP240141 |
| Date: | 2023 - 2025 |
| Title: | Image-based Prediction of Clinical Outcome After Stereotactic Ablative Radiation Therapy in Non-Small Cell Lung Cancer |
| Funding Source: | Siemens Project |
| Role: | Multiple Principal Investigator |
| ID: | MDA-2023-DTI-02 |
| Date: | 2023 - 2026 |
| Title: | Molecular and clinical approaches to target ALK positive residual disease |
| Funding Source: | Lung Cancer Research Foundation |
| Role: | Multiple Principal Investigator |
| Date: | 2023 - 2028 |
| Title: | Blood-radiomic signature for early detection of cancer recurrence after initial treatment in HPV-associated oropharyngeal squamous cell carcinoma (OPSCC) |
| Funding Source: | NIH/NCI |
| Role: | Multiple Principal Investigator |
| ID: | 1U01DE033334-01 |
| Date: | 2023 - 2027 |
| Title: | Clinical Validation Center for Lung Cancer Early Detection set Aside (U01CA27188) |
| Funding Source: | NIH/NCH |
| Role: | Co-I |
| ID: | 5U01CA271888-03 |
| Date: | 2023 - 2027 |
| Title: | Novel approaches for quantitating ALK+ residual disease after TKI therapy, modeling risk of PD, and testing new therapies |
| Funding Source: | Break Through Cancer |
| Role: | Group Leader |
| Date: | 2023 - 2024 |
| Title: | CCSG Supplement: Identify multi-modal machine learning model to guide immunotherapy for non-small cell lung cancer through federated learning |
| Funding Source: | NCI |
| Role: | Project Leader |
| Date: | 2023 - 2024 |
| Title: | Exploring the Impact of Genomic and Socioeconomic Factors on Lung Cancer Prognosis through Federated Learning |
| Funding Source: | Baylor College of Medicine |
| Role: | PI |
| Date: | 2023 - 2026 |
| Title: | Precision Immunoprevention of Indeterminant Pulmonary Nodules of Lung Cancer Through Radioimmunogenomic Analysis |
| Funding Source: | Permanent Health Funds |
| Role: | Multiple Principal Investigator |
| Date: | 2023 - 2026 |
| Title: | Accelerating Diagnosis and Personalized Treatment Through Development of an Integrative Predictive Model for Lung Cancer |
| Funding Source: | Lung Moon Shot |
| Role: | Project Leader |
| Date: | 2023 - 2028 |
| Title: | Integrated blood and radiomic subtyping to guide immunotherapy treatment selection and early response assessment in metastatic non-small cell lung cancer |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 5R01CA276178-03 |
| Date: | 2023 - 2024 |
| Title: | Microbiome Profile as a Predictive Biomarker for Treatment Outcomes in Early Stage Non-Small Cell Lung Cancer Treated with SABR alone vs SABR and Immunotherapy from a Phase II Randomized Control Trial |
| Funding Source: | Radiological Society of North America (RSNA) |
| Role: | Collaborator |
| Date: | 2023 - 2028 |
| Title: | A composite biomarker and radiomic score for risk stratification of indeterminate pulmonary nodules |
| Funding Source: | NIH/NCI |
| Role: | MPI |
| ID: | 1R01CA281896-01 |
| Date: | 2023 - 2026 |
| Title: | CT-based Deep Learning Model to Guide Immunotherapy in Non-Small Cell Lung Cancer |
| Funding Source: | QIAC Partnership in Research (QPR) |
| Role: | Co-PI |
| ID: | RCTS 62416 |
| Date: | 2023 - 2028 |
| Title: | Computational Imaging Approaches to Personalized Gastric Cancer Treatment |
| Funding Source: | NIH/NCI |
| Role: | Consult |
| ID: | R01CA269559 |
| Date: | 2023 - 2026 |
| Title: | Identify radiopathomics markers to guide immunotherapy for non-small cell lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP230194 |
| Date: | 2023 - 2023 |
| Title: | Recruitment of Established Investigator |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | Collaborator |
| ID: | RR220038 |
| Date: | 2023 - 2024 |
| Title: | Machine Learning to Guide First-line Immunotherapy in Lung Cancer |
| Funding Source: | Sabin Family Foundation |
| Role: | PI |
| Date: | 2023 - 2023 |
| Title: | Improving Nodular Lymphocyte Predominant Hodgkin Lymphoma Variants Diagnosis via Artificial Intelligence Tools |
| Funding Source: | SponsorMDACC Education & Training Pilot Grant Application |
| Role: | Mentor |
| Date: | 2023 - 2025 |
| Title: | LC220478: Application of artificial intelligence to the development of integrated radiomic and blood biomarkers to guide immunotherapy treatment in metastatic non-small cell lung cancer |
| Funding Source: | Department of Defense (DOD) |
| Role: | PI |
| ID: | LC220478 |
| Date: | 2022 - 2023 |
| Title: | Novel imaging methods to predict and phenotype post-COVID interstitial lung disease |
| Funding Source: | Radiological Society of North America (RSNA) |
| Role: | Co-PI |
| ID: | FP17327 |
| Date: | 2022 - 2027 |
| Title: | Clinical Validation Center for Lung Cancer Early Detection |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 5U01CA271888-03 |
| Date: | 2022 - 2027 |
| Title: | Multicenter radiomic-pathomic study to guide the use of chemo-immunotherapy for non-small cell lung cancer |
| Funding Source: | tbd |
| Role: | PI |
| ID: | 1R01CA277612-01 |
| Date: | 2022 - 2024 |
| Title: | Artificial intelligence of integrated radiographic and histopathological signature to improve the diagnosis of disease progression in chronic lymphocytic leukemia |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R21CA277698-01 |
| Date: | 2022 - 2024 |
| Title: | Radioimmunogenomic Analysis of Indeterminant Pulmonary Nodules for Precision Immunoprevention of Lung Cancer |
| Funding Source: | Fund for Innovation in Cancer Informatics (ICI) |
| Role: | PI |
| ID: | FP16204 |
| Date: | 2022 - 2027 |
| Title: | Interdisciplinary Translational Pre/Postdoctoral Program in Cancer Nanotechnology |
| Funding Source: | NIH/NCI |
| Role: | Mentor |
| ID: | 5T32CA196561-08 |
| Date: | 2022 - 2025 |
| Title: | The Linear Reference Region Model Improves Dynamic Contrast Enhanced MRI for Assessing Breast Cancer Response to Treatment |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01CA269355-01 |
| Date: | 2022 - 2027 |
| Title: | Radioimmunogenomic analysis of indeterminant pulmonary nodules for precision immunoprevention of lung cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA269475-01 |
| Date: | 2022 - 2022 |
| Title: | DetermaIO Analysis in Lung Cancer and Response to Immunotherapy |
| Funding Source: | Oncocyte |
| Role: | Co-I |
| Date: | 2022 - 2026 |
| Title: | Radioimmunogenomic analysis of indeterminant pulmonary nodules for precision immunoprevention of lung cancer |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RP220374 |
| Date: | 2022 - 2027 |
| Title: | A composite biomarker and radiomic score for risk stratification of indeterminate pulmonary nodules |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 1R01CA271214-01 |
| Date: | 2022 - 2023 |
| Title: | The effect of immunotherapy and pneumonitis on oral, gut, and lung microbiota and sleep quality in patients with non-small cell lung cancer undergoing sequential chemo-radiation and checkpoint inhibitor therapies |
| Funding Source: | IRG |
| Role: | Collaborator |
| ID: | RCTS# 60671 |
| Date: | 2022 - 2022 |
| Title: | Radioimmunogenomics to Predict Immunotherapy Efficacy in Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Radioimmunogenomic Habitat Phenotypes to Predict Efficacy of Neoadjuvant Immunotherapies in Non-Small Cell Lung Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5R01CA262425-04 |
| Date: | 2021 - 2023 |
| Title: | Developing novel, integrative approaches for expanding lung cancer screening and local consolidative therapy (LCT) |
| Funding Source: | Lung Moon Shot |
| Role: | Project Leader |
| Date: | 2021 - 2026 |
| Title: | Imaging Innovation for Head And Neck Cancer Evaluation & Treatment Delivery |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1P01CA254866-01A1 |
| Date: | 2021 - 2024 |
| Title: | Improving Lung Cancer Detection and Outcomes |
| Funding Source: | Major Donation Gift |
| Role: | Multiple Principal Investiagator |
| Date: | 2021 - 2026 |
| Title: | Integration of histopathology images and omics profiles to identify novel disease subtypes and predict melanoma progression through deep learning |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | R01CA262026-01 |
| Date: | 2021 - 2026 |
| Title: | COVID-19 Multi-center Imaging Consortium |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | 1R01HL159463-01 |
| Date: | 2021 - 2026 |
| Title: | The coevolution of dormant brain metastasis and host tissue ecosystems |
| Funding Source: | CRUK Cancer Grant Challenge |
| Role: | Co-I |
| Date: | 2021 - 2024 |
| Title: | UT System Rising STARs |
| Funding Source: | University of Texas |
| Role: | PI |
| Date: | 2020 - 2025 |
| Title: | Machine Learning Pipelines to Extract Quantitative Imaging Features from Serial CT Scans in Lung Cancer |
| Funding Source: | Tumor Measurement Initiative |
| Role: | Project Leader |
| Date: | 2020 - 2022 |
| Title: | Development of Integrated Bio-Imaging Markers of Response & Targets for Immunotherapy in NSCLC |
| Funding Source: | MDACC - Moon Shots |
| Role: | Co-I |
| Date: | 2020 - 2023 |
| Title: | Quantitative Imaging Biomarkers of Treatment Response and Prognosis in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | 5R00CA218667-05 |
| Date: | 2018 - 2020 |
| Title: | Quantitative Imaging Biomarkers of Treatment Response and Prognosis in Breast Cancer |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | K99CA218667 |
Patient Reviews
CV information above last modified July 11, 2025